Source study found

Story checked

Hormone therapy use may lead to fewer mood disturbances during the menopause transition (opens in a new tab)

medicalxpress.com · 2026-09-10

Short answerEvidenceSource

Short answer

Mixed

Mixed.

One claim goes further than the study. One other point was not covered by the paper.

4 supported
1 overstated
1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail

The story

Hormone therapy use may lead to fewer mood disturbances during the menopause transition

medicalxpress.com · 2026-09-10

The story’s checkable claims.

Read the original story

NewsLink checks it

Mixed

One claim overstates the study. Four of six check out. One claim the study doesn't address.

4 supported
1 overstated
1 not covered

Open claim evidence

The source study

Impact of hormone therapy on mood in a real-world clinical setting: a retrospective observational study.

Menopause (New York, N.Y.) · 2026

Open source record Open in Tessa

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

Reading mode

Scan verdicts. Open evidence only when needed.

Browse by verdict

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6OverstatedBased on the results, the researchers concluded that hormone therapy, when initiated for FDA-approved indications, resulted in improvements in psychological and sleep symptoms across the cohort.View evidenceHide evidence

Why this verdict

The paper profile supports observed improvements in psychological and sleep/mood-related symptoms after HT initiation in a retrospective pre–post cohort. However, the story’s wording that HT 'resulted in' improvements is a causal-strength framing. Given the observational, uncontrolled design, the evidence supports association and temporal improvement, not a definitive causal effect.

Study evidence

MRS psychological subdomain scores decreased significantly from baseline to follow-up after initiating systemic HT (P<0.001).

Claim 2 of 6Not coveredMood disturbances, including depressed mood, irritability, anxiety and mental exhaustion, are common during the menopause transition, affecting up to 68% of women.View evidenceHide evidence

As statedup to 68%

Why this verdict

The supplied abstract-level profile supports that depressed mood, irritability, anxiety, and mental exhaustion are menopause-transition mood disturbances and are common, but it does not provide or verify the specific 'up to 68%' prevalence figure.

Study evidence

MRS psychological subdomain scores decreased significantly from baseline to follow-up after initiating systemic HT (P<0.001).

Study evidence

Participants with severe baseline psychological symptoms had the largest mean improvement in MRS psychological subdomain score after initiating systemic HT.-3.85 (SE 0.223) mean change reported for the severe-baseline subgroup

Claim 3 of 6SupportedA new study suggests hormone therapy may improve mood symptoms in midlife.View evidenceHide evidence

Why this verdict

The profile reports a retrospective pre–post association between initiating systemic menopausal hormone therapy and improved MRS psychological subdomain scores, and says the authors interpret the findings as suggesting HT may improve mood symptoms in midlife. The story frames this as hedged and associational.

Study evidence

MRS psychological subdomain scores decreased significantly from baseline to follow-up after initiating systemic HT (P<0.001).

Claim 4 of 6SupportedThe study was published as a retrospective observational study in Menopause and involved 260 women.View evidenceHide evidence

As stated260 women

Why this verdict

The profile supports that the study was retrospective/observational and included 260 HT-naive clinic patients. The supplied scientific profile does not independently show the journal name, but the methodological and sample-size parts of the claim are supported by the abstract-level evidence.

Study evidence

MRS psychological subdomain scores decreased significantly from baseline to follow-up after initiating systemic HT (P<0.001).

Claim 5 of 6SupportedThe proportion of patients with severe mood symptoms decreased from 62.3% to 24.6%, with the greatest improvement in those with severe baseline symptoms.View evidenceHide evidence

As stated62.3% to 24.6%

Why this verdict

The profile directly reports that the severe mood symptom proportion fell from 62.3% to 24.6%, and that the largest mean improvement was seen among patients with severe baseline symptoms.

Study evidence

MRS psychological subdomain scores decreased significantly from baseline to follow-up after initiating systemic HT (P<0.001).

Study evidence

Claim 6 of 6SupportedTreatment response did not differ by psychiatric history, age, menopause stage or antidepressant use.View evidenceHide evidence

Why this verdict

The abstract-level profile states that treatment response did not differ by psychiatric history, age, menopausal stage, or baseline antidepressant use. The profile also notes that subgroup-specific estimates and statistical-test details are not provided at abstract depth, but the story’s claim matches the reported abstract statement.

Study evidence

Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

Short follow-up: mean follow-up was 4.5 months, so the evidence concerns short-term symptom change only.
The story caveats supplied do not mention the short follow-up duration, which matters for interpreting durability of mood improvement.
From Retrospective within-subject pre–post cohort; retrospective observational subgroup analyses
Confounding/analysis limitation: the abstract profile does not report adjustment for potential confounders or changes in concomitant treatments during follow-up.
Although the story notes the observational design, it does not specifically mention lack of reported adjustment or possible changes in other treatments, both of which are interpretation-changing for causal claims.
From Retrospective within-subject pre–post cohort; retrospective observational subgroup analyses
Generalizability limitation: single-center clinic-based sample and predominance of transdermal estradiol may limit applicability to other settings or HT regimens.
The story does not mention the single-center academic clinic sample or that most participants received transdermal estradiol, which limits how broadly the findings can be applied.
From Retrospective within-subject pre–post cohort; retrospective observational subgroup analyses

7 things the story did carry across

Study design: retrospective, observational, within-person pre–post analysis of MRS psychological subdomain scores before and after systemic HT initiation.
Population and setting: 260 HT-naive patients at an urban academic menopause center initiating systemic HT for FDA-approved indications.
Primary finding: MRS psychological subdomain scores decreased significantly from baseline to follow-up after HT initiation.
Severe symptom finding: proportion with severe mood symptoms decreased from 62.3% to 24.6%.
Subgroup finding: improvement was greatest among those with severe baseline symptoms.
Subgroup null findings: treatment response reportedly did not differ by psychiatric history, age, menopausal stage, or antidepressant use.
Key causal limitation: retrospective observational pre–post design without randomized or untreated control group limits causal inference.

Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataEvaluate whether initiating systemic menopausal hormone therapy (HT) in HT-naive patients is associated with improvement in mood-related symptoms (MRS psychological subdomain) in a real-world menopause clinic cohort.Retrospective within-subject pre–post cohortExpand

In plain English

Retrospective, within-person pre–post study of 260 HT-naive patients presenting to an urban academic menopause clinic (2023–2025) who completed the Menopause Rating Scale (MRS) psychological subdomain before and after initiating systemic menopausal hormone therapy (mostly transdermal estradiol). The study reports a statistically significant reduction in MRS psychological scores from baseline to follow-up (P<0.001), a decrease in the proportion with severe mood symptoms (MRS psychological subdomain score ≥7) from 62.3% to 24.6%, and the largest mean improvement among those with severe baseline symptoms (mean change -3.85, SE 0.223). Treatment response was reported to not differ by prior psychiatric history, age, menopausal stage, or baseline antidepressant use.

Key findings

MRS psychological subdomain scores decreased significantly from baseline to follow-up after initiating systemic HT (P<0.001).
The proportion of patients with severe mood symptoms (MRS psychological subdomain score ≥7) declined from 62.3% at baseline to 24.6% at follow-up.Change in severe-symptom proportion: 62.3% → 24.6%

What this piece can’t prove

Retrospective, observational pre–post design without a randomized or non-treated control group.
Mean follow-up of 4.5 months corresponds to short-term outcomes only.
Reliance on a patient-reported symptom scale (MRS); potential for reporting bias.
Abstract does not report adjustment for potential confounders or details on changes in concomitant treatments during follow-up.
Single-center, clinic-based sample (urban academic menopause center) and predominance of transdermal estradiol (96.5%) may limit generalizability to other settings or HT formulations.

2secondary dataAssess whether the mood response associated with HT differs across patient subgroups (baseline mood severity, psychiatric history, antidepressant use, age, menopausal stage).retrospective observational subgroup analysesExpand

In plain English

Retrospective clinic cohort subgroup analyses evaluating whether mood-score change after initiating systemic HT varied by baseline severity and by patient characteristics (psychiatric history, antidepressant use, age, menopausal stage). Improvement was largest among those with severe baseline psychological symptoms; the authors report no difference in treatment response across psychiatric history, age, menopausal stage, or concurrent antidepressant use.

Key findings

Participants with severe baseline psychological symptoms had the largest mean improvement in MRS psychological subdomain score after initiating systemic HT.-3.85 (SE 0.223) mean change reported for the severe-baseline subgroup
The proportion of participants meeting the threshold for severe mood symptoms (MRS psychological subdomain ≥7) decreased from 62.3% at baseline to 24.6% at follow-up.

What this piece can’t prove

Retrospective observational design limits causal inference and is susceptible to confounding.
Relatively short mean follow-up (4.5 months) limits assessment of longer-term mood effects.
Single-center clinic sample and high proportion (96.5%) receiving transdermal estradiol may limit generalizability to other settings or HT regimens.
Outcome based on patient-reported MRS psychological subdomain; potential reporting bias and lack of clinician-administered diagnostic assessment.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer